The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental models
- PMID: 23402400
- PMCID: PMC3599087
- DOI: 10.1186/1471-2334-13-83
The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental models
Abstract
Background: Seroreactivity, processes of seroconversion and seroreversion, in the context of HPV infection has been investigated in numerous studies. However, the data resulting from these studies are usually not accounted for in mathematical transmission models of various HPV types due to gaps in our understanding of the nature of seroreactivity and its implications for HPV natural history.
Methods: In this study we selected a number of simple but plausible compartmental transmission models of HPV-16, differing in assumptions regarding the relation between seropositivity and immunity, and attempted to calibrate them to Australian HPV seroprevalence data for females and males, as well as DNA prevalence data for females, using a Bayesian model comparison procedure. We ranked the models according to both their simplicity and ability to be fitted to the data.
Results: Our results demonstrate that models with seroreversion where seropositivity indicates only a partial or very short-term full protection against re-infection generate age-specific HPV DNA prevalence most consistent with the observed data when compared with other models.
Conclusions: Models supporting the notion that seropositive individuals are fully immune to reinfection demonstrated consistently inferior fits to the data than other models making no such assumption.
Figures



Similar articles
-
Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection.Vaccine. 2013 Apr 8;31(15):1931-6. doi: 10.1016/j.vaccine.2013.02.018. Epub 2013 Feb 19. Vaccine. 2013. PMID: 23434388
-
Inference of type-specific HPV transmissibility, progression and clearance rates: a mathematical modelling approach.PLoS One. 2012;7(11):e49614. doi: 10.1371/journal.pone.0049614. Epub 2012 Nov 21. PLoS One. 2012. PMID: 23185383 Free PMC article.
-
Prevalence of human papillomavirus antibodies in males and females in England.Sex Transm Dis. 2011 Jul;38(7):622-9. doi: 10.1097/OLQ.0b013e31820bc880. Sex Transm Dis. 2011. PMID: 21317688
-
Prevaccine era human papillomavirus types 6, 11, 16 and 18 seropositivity in the U.S.A., National Health and Nutrition Examination Surveys, 2003-2006.Sex Transm Infect. 2014 Sep;90(6):505-8. doi: 10.1136/sextrans-2013-051490. Epub 2014 Apr 19. Sex Transm Infect. 2014. PMID: 24748563
-
A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.Gynecol Oncol. 2008 Sep;110(3 Suppl 1):S18-25. doi: 10.1016/j.ygyno.2008.06.027. Epub 2008 Jul 23. Gynecol Oncol. 2008. PMID: 18653221 Review.
Cited by
-
Advances in HPV-Associated Cervical Cancer Dynamic Modelling for Prevention and Control Evaluation.China CDC Wkly. 2025 Feb 7;7(6):225-229. doi: 10.46234/ccdcw2025.035. China CDC Wkly. 2025. PMID: 39975937 Free PMC article.
References
-
- Munoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJF, Meijer CJLM. Research on Cancer Multicenter Cervical Cancer Study Group IA. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–527. doi: 10.1056/NEJMoa021641. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases